Polymorphisms in the IGF1 signalling pathway including the myostatin gene are associated with left ventricular mass in male athletes

British Journal of Sports Medicine

Volumn 45, Issue 1, 2011, Pages 36-41

  Karlowatz, Ruth Jessica ^a   Scharhag, Jürgen ^b,c   Rahnenführer, Jörg ^d   Schneider, Ulrich ^e   Jakob, Ernst ^e   Kindermann, Wilfried ^b   Zang, Klaus Dieter ^a  

^a SAARLAND UNIVERSITY   (Germany)

^b SAARLAND UNIVERSITY   (Germany)

^c UNIVERSITY OF POTSDAM   (Germany)

^d TU DORTMUND UNIVERSITY   (Germany)

^e Sportsclinic Hellersen ^*  (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

MYOSTATIN; SOMATOMEDIN C; SOMATOMEDIN C RECEPTOR;

ADULT; ARTICLE; CROSS-SECTIONAL STUDY; ECHOCARDIOGRAPHY; ECHOGRAPHY; FEMALE; GENETIC POLYMORPHISM; GENETICS; GENOTYPE; HEART LEFT VENTRICLE HYPERTROPHY; HUMAN; MALE; POINT MUTATION; SPORT;

ADULT; CROSS-SECTIONAL STUDIES; ECHOCARDIOGRAPHY; FEMALE; GENOTYPE; HUMANS; HYPERTROPHY, LEFT VENTRICULAR; INSULIN-LIKE GROWTH FACTOR I; MALE; MYOSTATIN; POINT MUTATION; POLYMORPHISM, GENETIC; RECEPTOR, IGF TYPE 1; SPORTS; YOUNG ADULT;

EID: 78650915244     PISSN: 03063674     EISSN: 14730480     Source Type: Journal    
DOI: 10.1136/bjsm.2008.050567     Document Type: Article

References (34)

1. Scharhag J, Schneider G, Urhausen A, et al. Athlete's heart: right and left ventricular mass and function in male endurance athletes and untrained individuals determined by magnetic resonance imaging. J Am Coll Cardiol 2002;40:1856-63.
2. Richey PA, Brown SP. Pathological versus physiological left ventricular hypertrophy: a review. J Sports Sci 1998;16:129-41.
3. McMullen JR, Jennings GL. Differences between pathological and physiological cardiac hypertrophy: novel therapeutic strategies to treat heart failure. Clin Exp Pharmacol Physiol 2007;34:255-62.
4. Jones JI, Clemmons DR. Insulin-like growth factors and their binding proteins: biological actions. Endocr Rev 1995;16:3-34.
5. Ren J, Samson W K, Sowers JR. Insulin-like growth factor I as a cardiac hormone: physiological and pathophysiological implications in heart disease. J Mol Cell Cardiol 1999;31:2049-61.
6. Toker A, Cantley LC. Signalling through the lipid products of phosphoinositide-3-OH kinase. Nature 1997;387:673-6.
7. McMullen JR, Shioi T, Huang WY, et al. The insulin-like growth factor 1 receptor induces physiological heart growth via the phosphoinositide 3-kinase (p110alpha) pathway. J Biol Chem 2004;279:4782-93.
8. Reiss K, Cheng W, Ferber A, et al. Overexpression of insulin-like growth factor-1 in the heart is coupled with myocyte proliferation in transgenic mice. Proc Natl Acad Sci USA 1996;93:8630-5.
9. Shioi T, Kang PM, Douglas PS, et al. The conserved phosphoinositide 3-kinase pathway determines heart size in mice. EMBO J 2000;19:2537-48.
10. Neri Serneri GG, Boddi M, Modesti PA, et al. Increased cardiac sympathetic activity and insulin-like growth factor-I formation are associated with physiological hypertrophy in athletes. Circ Res 2001;89:977-82.
11. Shyu KG, Ko WH, Yang WS, et al. Insulin-like growth factor-1 mediates stretchinduced upregulation of myostatin expression in neonatal rat cardiomyocytes. Cardiovasc Res 2005;68:405-14.
12. McPherron AC, Lawler AM, Lee SJ. Regulation of skeletal muscle mass in mice by a new TGF-beta superfamily member. Nature 1997;387:83-90.
13. Sharma M, Kambadur R, Matthews KG, et al. Myostatin, a transforming growth factor-beta superfamily member, is expressed in heart muscle and is upregulated in cardiomyocytes after infarct. J Cell Physiol 1999;180:1-9.
14. Cook SA, Matsui T, Li L, et al. Transcriptional effects of chronic Akt activation in the heart. J Biol Chem 2002;277:22528-33.
15. Gaussin V, Depre C. Myostatin, the cardiac chalone of insulin-like growth factor-1. Cardiovasc Res 2005;68:347-9.
16. Morissette MR, Cook S A, Foo S, et al. Myostatin regulates cardiomyocyte growth through modulation of Akt signaling. Circ Res 2006;99:15-24.
17. Karjalainen J, Mäntysaari M, Viitasalo M, et al. Left ventricular mass, geometry, and filling in endurance athletes: association with exercise blood pressure. J Appl Physiol 1997;82:531-7.
18. Frayling TM, Hattersley A T, McCarthy A, et al. A putative functional polymorphism in the IGF-I gene: association studies with type 2 diabetes, adult height, glucose tolerance, and fetal growth in U. K. populations. Diabetes 2002;51:2313-16.
19. Rosen CJ, Kurland E S, Vereault D, et al. Association between serum insulin growth factor-I (IGF-I) and a simple sequence repeat in IGF-I gene: implications for genetic studies of bone mineral density. J Clin Endocrinol Metab 1998;83:2286-90.
20. Vaessen N, Heutink P, Janssen JA, et al. A polymorphism in the gene for IGF-I: functional properties and risk for type 2 diabetes and myocardial infarction. Diabetes 2001;50:637-42.
21. Allen NE, Davey GK, Key TJ, et al. Serum insulin-like growth factor I (IGF-I) concentration in men is not associated with the cytosine-adenosine repeat polymorphism of the IGF-I gene. Cancer Epidemiol Biomarkers Prev 2002;11:319-20.
22. Bleumink GS, Schut AF, Sturkenboom MC, et al. A promoter polymorphism of the insulin-like growth factor-I gene is associated with left ventricular hypertrophy. Heart 2005;91:239-40.
23. Bonafè M, Barbieri M, Marchegiani F, et al. Polymorphic variants of insulin-like growth factor I (IGF-I) receptor and phosphoinositide 3-kinase genes affect IGF-I plasma levels and human longevity: cues for an evolutionarily conserved mechanism of life span control. J Clin Endocrinol Metab 2003;88:3299-304.
24. Schuelke M, Wagner KR, Stolz LE, et al. Myostatin mutation associated with gross muscle hypertrophy in a child. N Engl J Med 2004;350:2682-8.
25. Sahn DJ, De Maria A, Kisslo J, et al. Recommendations regarding quantitation in M-mode echocardiography: results of a survey of echocardiographic measurements. Circulation 1978;58:1072-83.
26. Lang RM, Bierig M, Devereux R B, et al. Recommendations for chamber quantification: a report from the American Society of Echocardiography's guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. J Am Soc Echocardiogr 2005;18:1440-63.
27. Teichholz LE, Kreulen T, Herman M V, et al. Problems in echocardiographic volume determinations: echocardiographic-angiographic correlations in the presence of absence of asynergy. Am J Cardiol 1976;37:7-11.
28. Balogh A, Derzbach L, Vannay A, et al. Lack of association between insulin-like growth factor I receptor G (+3174) A polymorphism and retinopathy of prematurity. Graefes Arch Clin Exp Ophthalmol 2006;244:1035-8.
29. R Development Core Team. R: A Language and Environment for Statistical Computing. R Foundation for Statistical Computing. Vienna, Austria, 2007. http://www. R-project.org.
30. den Dunnen JT, Antonarakis SE. Nomenclature for the description of human sequence variations. Hum Genet 2001;109:121-4.
31. Catalucci D, Latronico MV, Ellingsen O, et al. Physiological myocardial hypertrophy: how and why? Front Biosci 2008;13:312-24.
32. Fan W, Yanase T, Morinaga H, et al. Insulin-like growth factor 1/insulin signaling activates androgen signaling through direct interactions of Foxo1 with androgen receptor. J Biol Chem 2007;282:7329-38.
33. Leung KC, Johannsson G, Leong G M, et al. Estrogen regulation of growth hormone action. Endocr Rev 2004;25:693-721.
34. Sonnet E, Lacut K, Roudaut N, et al. Effects of the route of oestrogen administration on IGF-1 and IGFBP-3 in healthy postmenopausal women: results from a randomized placebo-controlled study. Clin Endocrinol (Oxf) 2007;66:626-31.